Background Selective patient recruitment can produce discrepancies between clinical trial
results and real-world effectiveness. Methods A systematic literature review and meta …

Background Vedolizumab [VDZ] is an anti-integrin monoclonal antibody effective in
ulcerative colitis [UC] and Crohn's disease [CD]. Several real-world experience [RWE] …

2. Methods Based on the GRADE workflow, the Guidelines Committee of ECCO [GuiCom]
selected a panel of 48 experts supported by a team of methodologists and librarians …

This article is the second in a series of two publications on the European Crohn's and Colitis
Organisation [ECCO] evidence-based consensus on the management of Crohn's disease …

The American Society of Colon and Rectal Surgeons (ASCRS) is dedicated to ensuring high-
quality patient care by advancing the science, prevention, and management of disorders …

Objective To study the role of α4β7 integrin for gut homing of monocytes and to explore the
biological consequences of therapeutic α4β7 inhibition with regard to intestinal wound …

Although the number of available therapies for the treatment of ulcerative colitis and Crohn's
disease (CD) continues to expand, a significant portion of patients with inflammatory bowel …

Since the introduction of the first anti-tumor necrosis factor antibodies in the late 1990s,
biologic therapy has revolutionized the medical treatment of patients with inflammatory …

Abstract Background and Aims The impact of vedolizumab, a gut-selective monoclonal
antibody, on postoperative outcomes is unclear. This study aimed to assess the impact of …

Background Ustekinumab, a monoclonal antibody targeting interleukins-12 and-23 is used
to treat adults with Crohn's disease [CD]. We determined the 30-day postoperative infectious …